Report Highlights

  • TVGN, formed in 2020, and based out of New Jersey, is a biotech company that went public earlier this year through a reverse merger. The company has potentially developed a breakthrough technology for developing off-the-shelf/cost-effective therapeutics for viral infections, various cancers, and neurologic diseases such as multiple sclerosis.
  • TVGN's patented technology harnesses the potency of cytotoxic T lymphocytes (CTLs), the body's natural defense against virus-infected and cancerous cells. We believe TVGN's approach has the potential to provide a more cost-effective and targeted treatment process compared to conventional options. The company’s CTLs  are genetically unmodified and sourced from third-party donors, enabling their off-the-shelf use for prompt treatment. Extracts from a single donor could potentially treat hundreds of patients.